Literature DB >> 11729016

Impact of generalized social anxiety disorder in managed care.

D J Katzelnick1, K A Kobak, T DeLeire, H J Henk, J H Greist, J R Davidson, F R Schneier, M B Stein, C P Helstad.   

Abstract

OBJECTIVE: The authors determined the costs associated with generalized social anxiety disorder in a managed care setting.
METHOD: A three-phase mail and telephone survey was conducted from July to October 1998 in two outpatient clinics of a large health maintenance organization (HMO). The survey assessed direct costs, indirect costs, health-related quality of life, and clinical severity associated with generalized social anxiety disorder, both alone and with comorbid psychopathology.
RESULTS: The weighted prevalence rate of current generalized social anxiety disorder was 8.2%. In the past year, only 0.5% of subjects with generalized social anxiety disorder had been accurately diagnosed. Yet 44.1% had a mental health specialty visit or had been prescribed an antidepressant, and psychiatric comorbidity was found in 43.6%. Noncomorbid generalized social anxiety disorder was associated with significantly lower health-related quality of life, work productivity, and earnings and greater utilization of health services; generalized social anxiety disorder with comorbid psychopathology was even more disabling. Suicide was attempted by 21.9% of subjects with noncomorbid generalized social anxiety disorder. Persons with average-severity generalized social anxiety disorder had probabilities of graduating from college that were 10 percentage points lower, earned wages that were 10% lower, and had probabilities of holding a technical, professional, or managerial job that were 14 percentage points lower than the comparison group.
CONCLUSIONS: In a community cohort of HMO members, generalized social anxiety disorder was rarely diagnosed or treated despite being highly prevalent and associated with significant direct and indirect costs, comorbid depression, and impairment.

Entities:  

Mesh:

Year:  2001        PMID: 11729016     DOI: 10.1176/appi.ajp.158.12.1999

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  46 in total

1.  Have drug companies hyped social anxiety disorder to increase sales. No: Efforts to relieve human suffering deserve rewards.

Authors:  D V Sheehan
Journal:  West J Med       Date:  2001-12

Review 2.  Familial risk factors in social anxiety disorder: calling for a family-oriented approach for targeted prevention and early intervention.

Authors:  Susanne Knappe; Katja Beesdo-Baum; Hans-Ulrich Wittchen
Journal:  Eur Child Adolesc Psychiatry       Date:  2010-10-06       Impact factor: 4.785

3.  Lifestyle and social network in individuals with high level of social phobia/anxiety symptoms: a community-based study.

Authors:  Christian A Falk Dahl; Alv A Dahl
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2009-05-26       Impact factor: 4.328

4.  Social context and the real-world consequences of social anxiety.

Authors:  Juyoen Hur; Kathryn A DeYoung; Samiha Islam; Allegra S Anderson; Matthew G Barstead; Alexander J Shackman
Journal:  Psychol Med       Date:  2019-08-19       Impact factor: 7.723

5.  A randomized effectiveness trial of cognitive-behavioral therapy and medication for primary care panic disorder.

Authors:  Peter P Roy-Byrne; Michelle G Craske; Murray B Stein; Greer Sullivan; Alexander Bystritsky; Wayne Katon; Daniela Golinelli; Cathy D Sherbourne
Journal:  Arch Gen Psychiatry       Date:  2005-03

6.  Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial.

Authors:  Murray B Stein; Mark H Pollack; Alexander Bystritsky; Jeffrey E Kelsey; Richard M Mangano
Journal:  Psychopharmacology (Berl)       Date:  2004-07-16       Impact factor: 4.530

7.  Psychometric properties of the mini-social phobia inventory.

Authors:  Elizabeth Seeley-Wait; Maree J Abbott; Ronald M Rapee
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2009

8.  Changes in Decentering Across Cognitive Behavioral Group Therapy for Social Anxiety Disorder.

Authors:  Sarah A Hayes-Skelton; Carol S Lee
Journal:  Behav Ther       Date:  2018-01-31

9.  Measurement of problems in activities and participation in patients with anxiety, depression and schizophrenia using the ICF checklist.

Authors:  Rosalía Tenorio-Martínez; María del Carmen Lara-Muñoz; María Elena Medina-Mora
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2009-01-27       Impact factor: 4.328

10.  Analysis of health-related quality of life and costs based on a randomised clinical trial of escitalopram for relapse prevention in patients with generalised social anxiety disorder.

Authors:  C François; S A Montgomery; N Despiegel; S Aballéa; J Roïz; P Auquier
Journal:  Int J Clin Pract       Date:  2008-08-28       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.